Is the GLP-1 pipeline progressing slowly? Gan & Lee Pharmaceuticals: GZR18 has the potential for superior weight reduction efficacy compared to multi-target drugs | Live coverage of the earnings conference.
At the earnings conference, the management of Gan & Lee Pharmaceuticals emphasized that the price regression of the company's insulin products in the follow-up volume procurement has driven the performance. In the face of doubts about the progress of GLP-1 pipeline research and competitiveness, Dou Kai, the General Manager of Gan & Lee Pharmaceuticals, stated that GZR18 injection has a weight loss effect that exceeds exenatide and dulaglutide, and has the potential to be superior to multi-target GLP-1RA drugs in weight loss efficacy.
Intense market competition combined with inventory reduction, Shenzhen Kangtai Biological Products' performance in the first half of the year has significantly declined | Interpretation of financial reports
①Affected by market competition and factors such as inventory reduction, the total revenue and net income attributable to the mother of shenzhen kangtai biological products declined in H1. ②The sales revenue of the business sector with the largest revenue contribution of the company decreased by more than 30% year-on-year. ③The accounts receivable of shenzhen kangtai biological products continued to climb, with a substantial decrease in cash flow.
Shenzhen Salubris Pharmaceuticals' H1 revenue increased by 20%, but net profit growth declined. The launch of two new drugs is facing negotiations with the government.|Interpretations of the financial report
1. In the first half of this year, the revenue of Shenzhen Salubris Pharmaceuticals increased by over 20%, but the net profit attributable to the parent only realized a growth of less than 2%; 2. During the reporting period, Shenzhen Salubris Pharmaceuticals had two innovative products approved for listing, and both products have now passed the national preliminary review this year; 3. Shenzhen Salubris Pharmaceuticals has 4 new drugs currently under market approval, including three chemical drugs and one biological drug.
Lepu Medical Technology's performance continued to decline in the first half of the year. It is expected that the revenue of the formulated business will further decrease. | Interpretations
① lepu medical technology once again submitted a half-year report with a decline in performance, and the revenue of the company's three major business sectors decreased year-on-year. ② Due to reasons such as the aging of product pipelines, lepu medical technology determines that the revenue of the formulation business sector may decrease to around 1.5 billion-1.6 billion yuan. ③ The company conducted self-inspection and rectification in response to the issues and requirements raised in the administrative supervision and regulation measures decision issued by the Beijing Securities Regulatory Bureau.
High inventory coupled with industry pressure, Chongqing Taiji Industry's H1 revenue and net profit both declined. | Interpretation of financial statements.
In the first half of this year, chongqing taiji industry's net profit was 0.495 billion yuan, a year-on-year decrease of 12.51%; The company stated that the poor performance in the first half of the year was mainly due to the high base of the same period last year and the high social inventory of some products.
Continued high investment in R&D and advancing market expansion, Autobio Diagnostics' first-half revenue and net profit both doubled, according to the announcement.
①Autobio Diagnostics achieved growth in both H1 revenue and net profit, with the proportion of R&D expenses in total revenue continuously increasing. ②The revenue proportion of the company's reagent business did not increase as expected. ③The company plans to add actual production support for specific subfields in the content of the 'Expansion Project of In Vitro Diagnostic Product Capacity' project.